Clinical research
Genentech’s checkpoint inhibitor Tecentriq combined with chemotherapy failed to hit the mark in a Phase III metastatic triple-negative breast cancer study.
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 7, 2020.
Denmark-based Lundbeck discontinued a mid-stage proof of concept study of a schizophrenia drug following an interim analysis of data that indicated the study will not achieve statistical significance in its primary endpoint.
A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment.
Several polls have suggested that as much as half of the U.S. population is unlikely to get the vaccine for a variety of reasons, including not feeling it is safe.
According to a warning from federal officials last week, dozens of drug companies, universities and medical device manufacturers owe more than a decade’s worth of data from clinical trials.
The company announced data from Phase I of its Phase I/II placebo-controlled trial of its vaccine with and without Matrix-M adjuvant.
Data security risks are growing as more and more clinical trials embrace telemedicine and other digital technologies.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
PRESS RELEASES